Finasteride increases PSA sensitivity by 10%

October 15, 2006

San Antonio-The Prostate Cancer Prevention Trial (PCPT) showed conclusively that finasteride (Proscar), a 5-alpha-reductase inhibitor indicated for the treatment of BPH, reduced the incidence of prostate cancer by nearly 25%. Continuing analysis of data from that trial now show the drug also enhances detection of prostate cancer by significantly improving the specificity of the PSA assay, according to a study published recently in the Journal of the National Cancer Institute (2006: 98:1128-33).